Sugi Predict

Sugi Predict / Compounds / SCHEMBL507617

SCHEMBL507617

SCHEMBL507617

CC(C)(C)OC(=O)NCc1ccc(Br)c(F)c1

nearest known ligand 0.47

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ GRM2 Q14416 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ NAMPT P43490 2/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ GAA P10253 1/20 0.43
▸ KDM4A O75164 1/20 0.43
▸ AAK1 Q2M2I8 1/20 0.43
▸ HDAC1 Q13547 1/20 0.42
▸ EPHX2 P34913 1/20 0.42
▸ NR1H4 Q96RI1 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ FPR3 P25089 1/20 0.42
▸ FPR2 P25090 1/20 0.42
▸ GLS O94925 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30457513 0.89 GRM2 (0.47) GRM2L3MBTL1NAMPTCA1CA2
SCHEMBL51488 0.89 GRM2 (0.47) GRM2L3MBTL1NAMPTCA1CA2
SCHEMBL24999627 0.87 GRM2 (0.49) GRM2L3MBTL1NAMPTGAAKDM4A
SCHEMBL29769069 0.87 GRM2 (0.49) GRM2L3MBTL1NAMPTGAAKDM4A
SCHEMBL1128630 0.86 CA2 (0.49) NAMPTCA1CA2AAK1
SCHEMBL31047884 0.86 GAA (0.41) GRM2CA1GAAAAK1EPHX2
SCHEMBL850268 0.84 MEN1 (0.47) GRM2L3MBTL1NAMPTCA1CA2
SCHEMBL29369357 0.84 HDAC1 (0.51) GRM2L3MBTL1NAMPTCA1CA2
SCHEMBL8249388 0.84 HDAC1 (0.48) GRM2L3MBTL1NAMPTCA1CA2
SCHEMBL18854481 0.84 EPAS1 (0.43) GRM2L3MBTL1NAMPTGAAKDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001875-A1 AMINOPYRIMIDINYL DERIVATIVES FOR THE TREATMENT OF PARKINSON'S DISEASE UNIV DUNDEE (GB) 2026-01-01 — — US disclosed
EP-4522603-A1 AMINOPYRIMIDINYL DERIVATIVES FOR THE TREAMENT OF PARKINSON'S DISEASE University Of Dundee (GB) 2025-03-19 — — EP disclosed
US-20250034150-A1 BTK INHIBITORS BIOGEN MA INC. 2025-01-30 — — US disclosed
CN-119325470-A Aminopyrimidinyl derivatives for the treatment of parkinson's disease 邓迪大学 2025-01-17 — — CN disclosed
EP-4429770-A1 BTK INHIBITORS Biogen MA Inc. (US) 2024-09-18 — — EP disclosed
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-18 — — US disclosed
WO-2023239645-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-12-14 — — WO disclosed
WO-2023239645-A1 SMARCA DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2023-12-14 — — WO disclosed
WO-2023218187-A1 AMINOPYRIMIDINYL DERIVATIVES FOR THE TREAMENT OF PARKINSON'S DISEASE UNIVERSITY OF DUNDEE (GB) 2023-11-16 — — WO disclosed
WO-2023218187-A1 AMINOPYRIMIDINYL DERIVATIVES FOR THE TREAMENT OF PARKINSON'S DISEASE UNIVERSITY OF DUNDEE (GB) 2023-11-16 — — WO disclosed
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist ELI LILLY AND COMPANY (US) 2012-02-02 — — US disclosed
CN-102329267-A 6-substituted 2,3,4, 5-tetrahydro-1H-benzo [d] aza as 5-HT2Creceptor agonists LILLY CO ELI 2012-01-25 — — CN disclosed
CN-102311387-A 6-substituted 2,3,4, 5-tetrahydro-1H-benzo [d] aza as 5-HT2Creceptor agonists LILLY CO ELI 2012-01-11 — — CN disclosed
US-8022062-B2 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists ELI LILLY AND COMPANY (US) 2011-09-20 — — US disclosed
US-8022062-B2 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists ELI LILLY AND COMPANY (US) 2011-09-20 — — US disclosed
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ARRAY BIOPHARMA, INC. 2009-04-16 — — US disclosed
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ARRAY BIOPHARMA, INC. 2009-04-16 — — US disclosed
CN-1934088-A As 5-HT2c6-substituted 2,3,4, 5-tetrahydro-1H-benzo [ d ] receptor agonists]Aza * LILLY CO ELI (US) 2007-03-21 — — CN disclosed
EP-1720836-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2006-11-15 — — EP disclosed
WO-2005082859-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2005-09-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099155-A1 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS HTR2C, HTR5A, HTR4 GRM2 121/4885L3MBTL1 3221/4885NAMPT 3730/4885
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF STAT4, STAT1, STAT3 GRM2 4273/4885L3MBTL1 3997/4885NAMPT 1472/4885
US-20260001875-A1 AMINOPYRIMIDINYL DERIVATIVES FOR THE TREATMENT OF PARKINSON'S DISEASE LRRK2, XIAP, PARK7 GRM2 1688/4885L3MBTL1 274/4885NAMPT 4804/4885
US-20250034150-A1 BTK INHIBITORS BTK, SYK, LYN GRM2 4766/4885L3MBTL1 3141/4885NAMPT 1413/4885
US-20120028961-A1 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist HTR2C, HTR4, HTR1A GRM2 125/4885L3MBTL1 3191/4885NAMPT 4611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.